Abstract
Vascular graft vasospasm is a lethal risk when using grafts for revascularization and reconstructive surgery. Revascularization is a treatment modality for ischemic diseases including Moyamoya disease that requires bypass surgery. Cerebrovascular graft transplantation carries a 5-10% risk of vasospasm, which can lead to devastating neurological sequelae. Here we report clinical outcomes associated with ex vivo botulinum toxin A (BoNT/A) treatment of arterial graft and provide reverse translational studies investigating the potential mechanisms of action of BoNT/A to reduce vasospasm. A retrospective review of the maintained database of patients undergoing surgery was performed for 63 patients. We used paired human vascular graft tissue for ex vivo BoNT/A studies to assess for spasmolytic downstream effectors; cleaved SNAP25, pMLC, pMYPT, ROCK1/2, and levels of catecholamines. We found that low-dose BoNT/A graft treatment is associated with 1) a reduction in clinical vasospasm (13.3%, p<0.05) without any identified safety concerns in patients, 2) an increase in arterial cleaved SNAP25, 3) reduced levels of pMLC and pMYPT, and 4) reduced levels of catecholamines. The mechanism of action leading to vascular relaxation is likely through pleiotropic vasodilatory pathways. The application of BoNT/A as a spasmolytic has potentially safe and broad applications across multiple surgical and scientific subspecialties.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This publication was made possible by National Institutes of Health R03 grant #5R03NS113090-02 (JJR) and the Alfred E. Mann Charities, Inc (JJR). Its contents are solely the responsibility of the authors.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
An IRB-approved (HS-18-00968, USC, University of Southern California), prospectively maintained database was used to identify and consent patients who had undergone EC-IC bypass with an autologous arterial interposition graft between July 2014 and January 2022. Interposition grafts were treated with BoNT/A beginning in March 2017. Information obtained included patient demographics, clinical presentation, indication for bypass, surgery performed, pre- and post-operative imaging characteristics, clinical outcomes (e.g., modified Rankin Scale [mRS] at follow-up), and complications.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors All data produced in the present work are contained in the manuscript
Non-standard Abbreviations and Acronyms
- 5HIAA
- 5-hydroxyindoleacetic acid
- BoNT
- botulinum toxin
- DLCFA
- descending branch of the lateral circumflex femoral artery
- EC-IC
- extracranial-to-intracranialI
- glmm
- generalized linear mixed-level models
- IC-IC
- intracranial-to-intracranial
- IF
- immunofluorescence
- IHC
- immunohistochemistry
- IQR
- interquartile range
- LC-MS
- liquid chomotography-mass spectrometry
- MAP
- mean arterial pressure
- mRS
- modified Rankin Scale
- NT
- neurotransmitter
- pMLC
- phosphorylated myosin light chain
- pMYPT1
- phosphorylated myosin phosphatase target subunit 1
- RAFCF
- radial artery fasciocutaneous flow-through free flap
- RAFF
- radial artery fascial flow-through free flap
- RAG
- radial artery
- rho kinase
- ROCK1/2
- SAH
- subarachnoid hemorrhage
- SD
- standard deviation
- SDS
- sodium dodecyl sulfate
- SNAP25
- synaptosomal-associated protein 25 kDa
- SRM
- selected reaction monitoring
- TBS
- Tris-buffered saline
- TH
- tyrosine hydroxylase
- VMA
- vanillylmandelic acid
- VSMCs: vascular smooth muscle cells.
